Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cytomegalovirus-loaded allogeneic natural killer cells + cytomegalovirus-loaded allogeneic dendritic cells
- Development stage
- Unknown
- Lead developer
- Seraph Research Institute
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous, Intradermal, Subcutaneous, Intratumoral
01
Overview
An investigational **combination cell immunotherapy** composed of allogeneic natural killer cells together with allogeneic dendritic cells that are loaded with cytomegalovirus antigens. The therapeutic concept is to use CMV antigen loading to stimulate anti-CMV immune recognition while leveraging the complementary functions of the two cellular components: NK cells provide innate cytotoxic activity against infected or malignant cells, and dendritic cells provide antigen presentation and immune priming that can amplify adaptive and innate anti-tumor or antiviral responses. Based on the name alone, this appears to describe a bespoke CMV-antigen-loaded allogeneic cell product combination rather than a clearly established commercial drug with a well-defined proprietary identity. Specific developer, manufacturer, formulation details, and clinical program information for this exact named product could not be confirmed.
- Other names
- CMV-loaded allogeneic natural killer cells + CMV-loaded allogeneic dendritic cells
02
Targets
pp65/HLA-A*02:01 (CMV pp65 peptide-HLA-A*02:01 complex)KIR (Killer-cell immunoglobulin-like receptors)CMV-TCR (Cytomegalovirus-specific T-cell receptor)
Beyond the preview
Go deeper on cytomegalovirus-loaded allogeneic natural killer cells + cytomegalovirus-loaded allogeneic dendritic cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cytomegalovirus-loaded allogeneic natural killer cells + cytomegalovirus-loaded allogeneic dendritic cells.